DMS-114 Cells

DMS-114 is a human small-cell lung cancer (SCLC) cell line with unique features distinguishing it from other SCLC subtypes. Recent research has indicated that DMS-114, previously classified within the YAP1-expressing SCLC category (SCLC-Y), harbors pathogenic mutations in SMARCA4, an ATPase subunit of the SWI/SNF chromatin-remodeling complex. These mutations are associated with the absence of RB1 mutations, contrary to the typical mutational landscape of SCLC, which commonly features concurrent TP53 and RB1 alterations. This cell line's profile includes reduced expression of SMARCA4 mRNA and protein, contributing to its reclassification as a SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) rather than a traditional SCLC. Morphological assessments have shown that DMS-114 aligns more closely with thoracic SMARCA4-UT, exhibiting traits such as lower neuroendocrine marker expression and a distinctive immunohistochemical profile. The revised classification of DMS-114 as a SMARCA4-deficient malignancy rather than SCLC has significant implications for its use as a preclinical model. It serves as an important resource for studying therapeutic strategies targeting SMARCA4-related pathways and investigating the biology of aggressive thoracic cancers that mimic SCLC. Unlike conventional SCLC, SMARCA4-deficient tumors, including DMS-114, often present with unique gene expression profiles marked by high YAP1 expression, loss of certain neuroendocrine markers, and distinct molecular vulnerabilities. This insight underscores the necessity of comprehensive molecular and histopathological analysis for accurate tumor classification and the development of effective treatment strategies.